An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy (CheckMate 451)
A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 451)
Sponsor: Bristol-Myers Squibb
This PHASE3 trial investigates Lung Cancer and is currently completed. Bristol-Myers Squibb leads this study, which shows 41 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
41 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 36 earlier versions
-
Mar 2022 — Feb 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Nov 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE3
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Jun 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE3
-
May 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE3
-
Apr 2020 — May 2020 [monthly]
Active Not Recruiting PHASE3
-
Mar 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE3
-
Feb 2020 — Mar 2020 [monthly]
Active Not Recruiting PHASE3
-
Jan 2020 — Feb 2020 [monthly]
Active Not Recruiting PHASE3
-
Dec 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE3
-
Nov 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE3
-
Aug 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE3
-
Jul 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE3
-
Jun 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE3
-
May 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE3
-
Jan 2019 — May 2019 [monthly]
Active Not Recruiting PHASE3
-
Dec 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE3
-
Nov 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE3
-
Oct 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE3
-
Sep 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
Status: Active Not Recruiting → Recruiting
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2018 — Mar 2018 [monthly]
Active Not Recruiting PHASE3
-
Dec 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Oct 2017 — Dec 2017 [monthly]
Recruiting PHASE3
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE3
-
Aug 2017 — Sep 2017 [monthly]
Recruiting PHASE3
-
Jul 2017 — Aug 2017 [monthly]
Recruiting PHASE3
-
May 2017 — Jul 2017 [monthly]
Recruiting PHASE3
-
Apr 2017 — May 2017 [monthly]
Recruiting PHASE3
-
Mar 2017 — Apr 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Oct 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Ono Pharmaceutical Co. Ltd
For direct contact, visit the study record on ClinicalTrials.gov .